Why is Cohance Life falling/rising?

As of 27-Jun, Cohance Lifesciences Ltd is experiencing a decline in its stock price, currently at 944.05, which represents a decrease of 54.75 or 5.48%. The stock has underperformed its sector by 6.36% today and has fallen after three consecutive days of gains. It reached an intraday low of Rs 931.75, reflecting a drop of 6.71%. Over the past week, the stock has decreased by 4.49%, and its performance over the last month shows a significant decline of 13.41%. Despite a strong one-year return of 20.28%, the company has faced challenges, including a 39.8% drop in PAT compared to the previous four-quarter average and a poor long-term growth outlook with an annual operating profit decline of 3.76% over the last five years.
In the broader market context, the Sensex has increased by 2.00% over the past week and 3.07% over the past month, indicating that the market is generally performing well while Cohance Lifesciences is struggling. The stock's liquidity appears to be sufficient for trading, but there has been a notable decline in investor participation, with delivery volume falling by 74.66% against the five-day average. Furthermore, the stock is trading at a premium compared to its peers, with a high price-to-book value of 21.3, which may deter potential investors. Overall, the combination of poor short-term performance, declining profitability, and high valuation relative to peers contributes to the stock's downward movement.